Nanologica (NICA) Q4 2024 earnings summary

Executive summary

• Achieved record net sales of SEK 14.5 million for 2024, driven by strong demand for chromatography products, especially NLAB SagaⓇ, with SEK 6.7 million in Q4.

• Operating loss narrowed to SEK -59.3 million for the year from SEK -70.0 million in 2023, aided by higher sales and improved inventory value.

• Rights issue completed in Q4, raising SEK 76.5 million in cash and offsetting SEK 15.9 million in loans, significantly strengthening liquidity.

• Major customer in China placed five orders for NLAB SagaⓇ since June 2024, totaling SEK 18 million, validating product competitiveness.

Financial highlights

• Net sales for Q4: SEK 6,715 thousand (75); full year: SEK 14,538 thousand (1,443), year-over-year growth.

• Operating loss for Q4: SEK -11,890 thousand (-35,638); full year: SEK -59,255 thousand (-69,963), improved year-over-year.

• Loss after tax for Q4: SEK -14,033 thousand (-36,839); full year: SEK -65,629 thousand (-75,157).

• Earnings per share (basic/diluted) for Q4: SEK -0.19 (-1.02); full year: SEK -1.32 (-2.08).

• Cash and cash equivalents at year-end: SEK 48,430 thousand (10,054).

Outlook and guidance

• Large-scale silica production enables higher delivery volumes and market-based lead times, supporting further commercialization of NLAB SagaⓇ.

• Continued focus on increasing production volumes and improving margins in 2025 and 2026 to meet growing demand.

• Management expects good opportunities for significant sales growth in coming years.